C11100P

DMT-dC(bz) Pharmadite^®

• Synonym(s): DMT-dC(bz) Phosphoramidite, N-benzoyl-5′-O-[bis(4-methoxyphenyl)phenylmethyl]-2′-deoxycytidine, 3′-[2-cyanoethyl N,N-?bis(1-methylethyl)phosphoramidite]
• Empirical Formula (Hill Notation): C₄₆H₅₂N₅O₈P
• Molecular Weight: 833.91
• MDL number: MFCD00036315
• UNSPSC Code: 12352200
• PubChem Substance ID: 329774847
• NACRES: NA.51

Properties

• biological source: non-animal source (no BSE/TSE risk)
• Quality Level: 300
• type: for DNA synthesis
• product line: Proligo Reagents
• assay: ≥99.5% (reversed phase HPLC); >99.5% (³¹P-NMR)
• form: powder or granules
• technique(s): oligo synthesis: suitable
• impurities: >= 170ppm, none detected (S/N <2.5); ≤0.1% P(III) 100-169ppm (³¹P-NMR); ≤0.1% single unspecified Imprity (reversed phase HPLC); ≤0.3% dC2 (reversed phase HPLC, DMT-dC(bz) cyanoethyl-H-posphonate); ≤0.3% dC3 (reversed phase HPLC, DMT-dC(bz) phosphoramidate); ≤0.3% dC5 (reversed phase HPLC, O3′-Benzoyl-O5′-DMT-dC(bz)); ≤0.30 wt. % water content (Karl Fischer); ≤0.5% P(V) -25-99ppm (³¹P-NMR); ≤3.0 wt. % residual solvent content
• color: white to off-white
• solubility: soluble, clear
• suitability: conforms to structure for H-NMR; conforms to structure for LC-MS
• nucleoside profile: base: deoxycytidine; base protecting group: benzoyl; 2' protecting group: none; 5' protecting group: DMT; deprotection: standard
• storage temp.: 2-8°C
• SMILES string: COc1ccc(cc1)C(OC[C@H]2O[C@H](C[C@@H]2OP(OCCC#N)N(C(C)C)C(C)C)N3C=CC(NC(=O)c4ccccc4)=NC3=O)(c5ccccc5)c6ccc(OC)cc6
• InChI: 1S/C46H52N5O8P/c1-32(2)51(33(3)4)60(57-29-13-27-47)59-40-30-43(50-28-26-42(49-45(50)53)48-44(52)34-14-9-7-10-15-34)58-41(40)31-56-46(35-16-11-8-12-17-35,36-18-22-38(54-5)23-19-36)37-20-24-39(55-6)25-21-37/h7-12,14-26,28,32-33,40-41,43H,13,29-31H2,1-6H3,(H,48,49,52,53)/t40-,41+,43+,60?/m0/s1
• InChI key: PGTNFMKLGRFZDX-SALLYJDFSA-N

Description

General description

DMT-dC(bz) Pharmadite^® is a Pharmadite^® product line that represents a new class of standard protected DNA phosphoramidites designed with highly controlled impurity profiles and exceptional overall purity.Pharmadite phosphoramidites are characterized by their exceptional purity and well-defined impurity profile. In particular, they are essentially free fromcontaminants that interfere in coupling reactions, such as other nucleosidic or non-nucleosidic phosphoramidites (P(III)-contaminants). All remainingimpurities in Pharmadite phosphopramidites, if present, are identified, characterized, and quantified. The impact of any such defined impurities on the synthesis of oligonucleotides is well understood and has been shown to be insignificant.

Legal Information

Pharmadite is a registered trademark of Merck KGaA, Darmstadt, Germany

Safety Information

• Storage Class: 11 - Combustible Solids
• wgk_germany: WGK 1
• flash_point_f: Not applicable
• flash_point_c: Not applicable